Iovance Biotherapeutics (IOVA) Insider Maynard Buys 90,316 Shares

Ryan Maynard recently purchased 90,316 shares of IOVA on June 16, 2026. This insider buying event occurred as the stock traded around $3.93. Maynard's acquisition wasn't part of a pre-planned trading scheme, indicating personal confidence in the company's prospects.

Insider Buying and Selling at Iovance Biotherapeutics, Inc.

On June 16, 2026, several insiders at IOVA made notable transactions. Ryan Maynard acquired 90,316 shares, while Raj Puri, the Chief Regulatory Officer, bought 15,000 shares. Iain Dukes added 180,632 shares to his holdings. Athena Countouriotis and Michael Weiser each bought 90,316 shares. These transactions were not executed under Rule 10b5-1 plans. Earlier, on June 5, 2026, Friedrich Finckenstein, the Chief Medical Officer, sold 7,813 shares.

Other Institutional Activity in IOVA

Several institutional investors have been active in IOVA recently. BlackRock, Inc. increased its holdings by 1,562,380 shares, reaching a total of 31,080,505 shares valued at approximately $109.1 million. MHR Fund Management LLC maintained its position at 28,967,103 shares, valued at about $101.7 million. State Street Corp reduced its stake by 2,713,337 shares, leaving it with 17,448,108 shares worth $61.2 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both established new positions, each holding over 11 million shares.

Analysts Set New Price Targets

Analysts have been active in evaluating IOVA. On May 8, 2026, Chardan Capital maintained its 'buy' rating with a $14 price target. UBS held its 'hold' rating with a $4 target on March 5, 2026. Citizens upgraded the stock to 'buy' with a $5 target on March 3, 2026. Barclays has consistently maintained a 'buy' rating, with recent targets ranging from $9 to $11.

Bottom Line

Ryan Maynard's purchase of IOVA shares highlights ongoing insider interest in the company. Institutional investors have shown mixed activity, with some increasing their stakes and others reducing them. Analysts remain cautiously optimistic, maintaining mostly 'buy' ratings with varied price targets. Investors often track these insider and institutional activities for insights, but it's important to remember that these filings reflect past actions and may not indicate current positions.